A Phase I Study to Assess the Pharmacokinetics of IK-1001 in Subjects With Impaired Renal Function Following a Continuous 3-hour Intravenous Infusion

Trial Profile

A Phase I Study to Assess the Pharmacokinetics of IK-1001 in Subjects With Impaired Renal Function Following a Continuous 3-hour Intravenous Infusion

Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2016

At a glance

  • Drugs Sodium sulfide (Primary)
  • Indications Ischaemic heart disorders; Reperfusion injury
  • Focus Pharmacokinetics
  • Sponsors Ikaria Holdings
  • Most Recent Events

    • 21 May 2015 Status changed from completed to discontinued, as reported by ClinicalTrials.gov.
    • 18 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Feb 2010 Planned end date changed from 1 Feb 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top